Mycenax Biotech (4726) — Capital Reinvestment Ratio
Latest as of March 2025:
5.90x
Mycenax Biotech (4726) has a Capital Reinvestment Ratio of 5.90x as of March 2025, meaning it reinvests 6% of its operating cash flow (NT$14.29 Million) in capital expenditures (NT$84.30 Million). See cash generation quality of Mycenax Biotech to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
5.90x
Capex / Operating Cash Flow
Operating Cash Flow
NT$14.29 Million
TWD
Capital Expenditures
NT$84.30 Million
TWD
Data as of
Mar 2025
Most recent filing
Mycenax Biotech Capital Reinvestment Ratio (2020–2020)
This chart tracks Mycenax Biotech's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Mycenax Biotech (2020–2020)
Year-by-year Capital Reinvestment Ratio for Mycenax Biotech from 2020 to 2020. For live market cap and broader valuation context, see 4726 market cap.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2020 | 1.49x | NT$174.17 Million | NT$260.22 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow